**CName of journal:** *World Journal of Gastroenterology*

**ESPS Manuscript NO: 30283**

**Manuscript Type:****ORIGINAL ARTICLE**

***Basic Study***

**Autoantibody profiles in autoimmune hepatitis and chronic hepatitis C identifies similarities in patients with severe disease**

Amin K *et al.* Autoantibodies in CHC and AIH

Kawa Amin, Aram H Rasul, Ali Hattem, Taha AM Al-Karboly, Taher E Taher, Jonas Bystrom

**Kawa Amin**, Department of Medical Science, Respiratory Medicine and Allergology, Clinical Chemistry and Asthma Research Centre, Uppsala University and University Hospital, SE-751 85 Uppsala, Sweden

**Kawa Amin**, Department of Microbiology/Immunology, School of Medicine, University of Sulaimani, Sulaimani 334, Iraq

**Aram H Rasul,** Laboratory Department, General Hospital of Derbandixan, Derbandixan 332, Iraq

**Ali Hattem,** Department of Community Health, Sulaimani Polytechnic University, Sulaimani 334, Iraq

**Taha AM Al-Karboly,** Department of Medicine, School of Medicine, Faculty of Medical Sciences, University of Sulaimani; Kurdistan Center for Gastroenterology and Hepatology, Sulaimani 334, Iraq

**Taher E Taher, Jonas Bystrom**, Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and the London, Queen Mary, University of London, Charterhouse Square, EC1M 6BQ London, United Kingdom

**Author contributions:** Amin K, Rasul AH, Hattem A, Al-Karboly TAM, Taher TT and Bystrom J designed the experiments for this study; Hattem A, Rasul AH and Al-Karboly TAM performed the experiments; Amin K, Rasul AH, Hattem A, Al-Karboly TAM, Taher TE and Bystrom J analysed the data and wrote the manuscript.

**Supported by** Bror Hjerpstedt Foundation, Sweden.

**Institutional review board** **statement****:**Approval of the study was received from the Ethics board and the Office of the vice president for scientific affairs and postgraduate studies at the Sulimani University.

**Conflict-of-interest** **statement:** The authors declare no conflict to interest.

**Data sharing statement:** If received a written request, for scientific purposes, the authors would be able to share the (anonymized) raw data used in this manuscript.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Correspondence to: Kawa Amin, PhD, Assistant Professor,** Department of Microbiology/Immunology, School of Medicine, University of Sulaimani, Sulaimani 334, Iraq. kawa.amin@univsul.edu.iq

**Telephone:** +98-964-7701958515

**Received:** September 23, 2016

**Peer-review started:** September 26, 2016

**First decision:** October 28, 2016

**Revised:** November 17, 2016

**Accepted:** December 8, 2016

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To determine how the auto-antibodies (Abs) profiles overlap in chronic hepatitis C infection (CHC) and autoimmune hepatitis (AIH) and correlate to liver disease.

***METHODS***

Levels of antinuclear Ab, smooth muscle Ab and liver/kidney microsomal-1 (LKM-1) Ab and markers of liver damage were determined in the sera of 50 patients with CHC infection, 20 AIH patients and 20 healthy controls using ELISA and other immune assays.

***RESULTS***

We found that AIH patients had more severe liver disease as determined by elevation of total IgG, alkaline phosphatase, total serum bilirubin and serum transaminases and significantly higher prevalence of the three non-organ-specific autoantibodies (auto-Abs) than CHC patients. Antinuclear Ab, smooth muscle Ab and LKM-1 Ab were also present in 36% of CHC patients and related to disease severity. CHC cases positive for auto-Abs were directly comparable to AIH in respect of most markers of liver damage and total IgG. These cases had longer disease duration compared with auto-Ab negative cases, but there was no difference in gender, age or viral load. KLM-1+ Ab CHC cases showed best overlap with AIH.

***CONCLUSION***

Auto-Ab levels in CHC may be important markers of disease severity and positive cases have a disease similar to AIH. Auto-Abs might have a pathogenic role as indicated by elevated markers of liver damage. Future studies will unravel any novel associations between these two diseases, whether genetic or other.

**Key words***:*Autoantibody; Inflammatory diseases; Immune system; Hepatitis C virus; Smooth muscle antibody; Anti-nuclear antibody; Liver/kidney microsomal-1 autoantibody

**© The Author(s) 2016.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** This paper aim to determine how patients with chronic hepatitis C and autoimmune hepatitis produce autoantibodies; Disease duration in chronic hepatitis C is linked to disease severity and autoantibodies; and patients with severe chronic hepatitis C resemble autoimmune hepatitis.

Amin K, Rasul AH, Hattem A, Al-Karboly TAM, Taher TE, Bystrom J. Autoantibody profiles in autoimmune hepatitis and chronic hepatitis C identifies similarities in patients with severe disease. *World J Gastroenterol* 2016; In press

**INTRODUCTION**

Antibodies are a vital part of the immuneresponse for recognition and elimination of invading organisms. However, when the immune system is dysfunctional, it can develop antibodies that react to self. The development of autoantibodies (auto-Abs) generally occurs during auto-immune disease, but their induction can also be a consequence of a chronic infection in susceptible individuals. A number of auto-Abs with different specificities have been identified. As some auto-Abs occurrence in plasma is disease specific, they can be used in the diagnosis and classification of autoimmune diseases[1-3]. The hepatitis virus C (HCV) causes liver damage by inducing cirrhosis and can also lead to hepatocellular carcinoma. Recent studies have demonstrated that the virus may be involved in loss of tolerance to self-antigens and thereby promotion of auto-Ab production[4-6]. In particular, non-organ-specific auto-Abs (NOSAs) including smooth muscle ab (SMA), anti-nuclear ab (ANA) and liver/kidney microsomal-1 (LKM-1) Abs are common and frequently found in sera of patients with chronic HCV (CHC)[7,8]. NOSA in HCV-infected patients correlate with the severity of necro-inflammation, fibrosis development, markers of liver damage: aspartate transaminase (AST) and alanine transaminase (ALT), alkaline phosphatase (AP) and levels of IgG[9].

Clinical and laboratory features of CHC can sometimes lead to a mistaken diagnosis of autoimmune hepatitis (AIH). AIH is characterized by a liver-specific autoimmune response, infiltrating immune cells, auto-Abs in circulation, elevated immunoglobulin and serum transaminase level, and a favourable response to immunosuppression[10,11]. In AIH; ANA, SMA, and LKM-1 Abs can differentiate the severity of the disease. The existence of detectable hepatitis C viral load with or without circulating antibodies specific to HCV can often be used to differentiate CHC from AIH[12]. These two conditions, CHC and AIH involve different management strategies; chronic HCV infection has until recently often been treated with interferon-α (IFN-α) which can provoke liver auto-immunity. The HCV infection can in a few cases develop into AIH, suggesting that the liver cells are damaged not only by the infection but also by an immune reaction to self[13,14]. AIH on the other hand, requires immunosuppression, a treatment that could induce viral replication in cases of co-infection[11,14].

In this study, we have assessed the prevalence of ANA, SMA and LKM-1 Abs in CHC and AIH patients and correlated this with markers of liver disease to determine any overlapping features. In the study, disease severity, immunoglobulin levels and disease duration were assessed. We found that the auto-Ab profile was directly associated with severity of disease in both groups of patients and that subgroups within the patients showed a significant overlap in respect to the laboratory markers assessed.

**MATERIALS AND METHODS**

A total of 70 patients and 20 healthy controls were recruited during the duration of this study (Table 1). These included 50 patients diagnosed with CHC and 20 patients with AIH. Approval of the study was received from the Ethics board and the Office of the vice president for scientific affairs and postgraduate studies at the Sulimani University. CHC patients were diagnosed based on anti-HCV antibody positivity and by assessment of their HCV RNA viral load. Patients with liver damage due to excessive alcohol consumption, hepatotoxic drugs, or human immunodeficiency virus infections were excluded from the study. Patients diagnosed positive for hepatitis B surface antigen (HBsAg) were also excluded. The diagnosis of AIH was based on the criteria established by the international autoimmune hepatitis group. This includes predominant elevation of serum aminotransferase and IgG, exclusion of viral hepatitis, toxic or alcoholic liver injury and with a liver biopsy confirming lymphocyte infiltration indicative of autoimmune disease[15]. Some patients were diagnosed for the first time when enrolled in the study while others had been undergoing treatment for between two and 11 years. Information of age and gender was recorded for each patient. Twenty healthy gender- and age matched blood donors served as controls.

***Enzyme linked immunosorbent assay and other assays***

SMA, ANA and LKM-1 Ab in serum were assayed by enzyme linked immunosorbent assay (ELISA) according to the manufacturer’s instructions (CUSABIO, Wuhan, China). Total IgG and IgM was estimated quantitatively using a biochemical assay according to the manufacturer’s instructions (VITAL Diagnostics, Puteaux, France). Serum AP, Alanine transaminase (ALT), Aspartate transaminase (AST), serum albumin (sAb) and total serum bilirubin (TSB) was quantitatively determined using a biochemical assay (BIOLABO, Maizy, France).

***Statistical analysis***

Analysis of data was performed by using software package SPSS (Statistical Package for Social Science) version 21. Normal distribution of the data was determined using D'Agostino & Pearson omnibus normality test. Results are expressed as mean ± standard deviation (mean ± SD). Statistical differences were determined by Duncan’s test for multiple comparisons after analysis of variance (ANOVA). Significant differences between groups were determined using the chi-square test. A *P* value less than 0.05, 0.01 or 0.001 respectively, were considered statistically significant at levels.

**RESULTS**

In the aim of discovering overlapping features comparing CHC and AIH cases such patients were recruited and sera gathered for analysis of auto-Ab levels and levels of markers of liver damage. In Table 1 is shown the demographics of the CHC-, the AIH- and the healthy control-group (HC). The CHC group included 50 patients (48% female) and the mean age were 33.4 ± 2.4 years. In agreement with other studies, AIH was more common among females (gender ratio 3:1) with males being older when diagnosed (47.0 ± 3.1 years). There were no significant difference in age or gender comparing patients and HC.

One or more of the auto-Abs was detected in 36% of CHC patients’ serum (9 male, 9 female, Table 2). Reactivity for ANA was the most frequent (32%, 7 male, 9 female) while LKM-1 Ab was detectable in 22% (4 male, 7 female) and SMA in 8% (1 male, 3 female) of the cases. Also 20% of the healthy controls were positive for ANA (2 male, 2 female) but non for LKM-1 or SMA. A statistical analysis using the Chi-square test showed that there was no significant difference in the level of ANA comparing the control group and the CHC group. In AIH patients, 75% (3 male, 12 female) had at least one type of auto-Ab. ANA was also for these patients the most frequently detected, 65% (3 male, 10 female). LKM-1 Ab was identified in 9 cases (45%) all of which were female. SMA was not detected in any of the AIH patient’s serum. A statistical analysis showed significant differences between the AIH and CHC groups of patients regarding auto-Ab prevalence (AIH patients were more often positive for the auto-Abs, *P* = 0.0031, see Table 2). The level of ANA and LKM-1 however tended to be highest in CHC patients plasma (for ANA level in CHC: 4.6 ± 2.7 pg/mL and in AIH, 3.3 ± 1.8 pg/mL, for LKM-1, level in CHC: 4.9 ± 2.8 and in AIH: 4.0 ± 1.4 pg/mL).

Next, we assessed the level of IgG in the patient’s serum. As expected, the highest level was found in the serum from the AIH patients (see Table 3). There was no significant difference in IgG level comparing CHC and AIH, but the levels were significantly higher than the healthy controls (see Table 3). In contrast, although significantly higher than the healthy controls, the level mean concentration of IgM remained in a normal range in the CHC and AIH groups. The AIH patients IgM level was significantly higher than the CHCs’ and the HCs’.

All of the markers of liver damage (AP, ALT AST, and TSB) except Albumin assessed in the serum were elevated above the level of the HC’s for both the AIH patients and the CHC patients (Table 4). However, in the AIH group, the levels of these markers were significantly higher than in the CHC group (Duncan’s test, *P <* 0.05). Only the level of TSB was at a similar level in both patient groups.

To determine whether the presence of auto-Abs in the CHC group was associated with worse disease progression we compared the level of liver damage markers from patients with and without auto-Abs. We found that that the duration of infection was twice as long for patients with auto-Abs compared to without. Furthermore, patients with auto-Abs had significantly higher levels of IgG, AP, AST, ALT and TSB (Table 5). This finding is in agreement with that of a previous study[9]. The age and gender of the patients, viral load, IgM, and serum albumin did however not differ in the two CHC subgroups.

The CHC patients with auto-Abs, the longest duration of infection and the highest level of markers of liver damage were directly compared with the AIH patients (see Table 5). These two groups were remarkably similar in respect to IgG levels and most markers of liver injury (Table 6). Only the levels of IgM and TSB were higher in the AIH patients (*P <* 0.05).

Further, we found that the LKM-1 Abs present only in sera of female patients in the AIH group. LKM-1 Ab positive AIH patients are often young females with worse prognosis[16,17]. In our study, 22% of the CHC patients were positive for LKM-1 Ab. However, such positivity was found among both male and female subjects (5 male, 6 female). Importantly, our immunological and biochemical analysis revealed that there were no significant differences between these two subgroups of LKM-1+ CHC and AIH in respect of IgG, AP, AST, ALT, Albumin or TSB. The only difference was the concentration of IgM (Table 7).

**DISCUSSION**

In this study, we have shown that certain patients with chronic hepatitis C infection develop an auto-Ab profile similar to that of AIH. This group of patients had longer disease duration and more extensive liver damage, thereby sharing many features of AIH. The comparison of LKM-1 Ab positive patient emphasised the similarity between severe cases of CHC and the AIH group. Only IgM levels discriminated these two groups of patients. Such knowledge is important when interpreting biomarker results from patients with liver disease. Furthermore, the findings suggest an underlying similarity in disease aetiology in these cases of auto-Ab positive CHC and AIH patients.

It is important to differentiate between CHC and AIH as their treatment is completely different[18]. Thus although autoantibodies and elevated liver enzymes might suggest a diagnosis of AIH, patients require further investigation to exclude CHC. When comparing NOSA production from the CHC and AIH patients in our study there was a significant difference, underscoring the overall more severe progression of the disease in the patients with autoimmune disease. In other studies of CHC 6%-41% was positive for ANA, 5%-66% for SMA, and up to 86% for LKM-1 Abs[12,19-22]. There are several reasons to explain why such a variation in levels of auto-Abs has been observed. ANA measured by indirect immune-fluorescence of Hep-2 cells or by different Elisas produce variable results dependent of the method used[23]. Regional differences in prevalence of autoimmune manifestations in HCV might influence the results[5,24]. Furthermore, differences in auto-Ab levels might be due to the local ethnic background. Hence, in HCV infected patients from Crete or Sweden, very few showed positivity for LKM-1[25,26].

It is not known why 36% of the CHC infected patients in our study develop auto-Abs. Liver damage in CHC cases result in release of auto-antigens to which the immune system can react[27]. As stated above, infection duration might be one factor in the development of auto-Abs. Other studies have however failed to identify an association between infection duration and NOSA levels[9,28]. Other factors such as presence of the HLR-DR3 genotype might be more important for auto-Ab development[29].

AIH is known to induce liver damage[11]. CHC patients with auto-Abs and longstanding disease had liver damage at the same level as the AIH cases. The appearance of auto-Ab positive CHC patients can show so high similarity to AIH that they can be misdiagnosed. This is especially the case for patients with extrahepatic symptoms[10,11]. Presence of circulating antibodies specific to HCV is chief for correct diagnosis[12]. The liver damage experienced during AIH is induced by infiltrated inflammatory cells which can be visualized by a liver biopsy[11]. Indeed a liver biopsy is necessary for confirmation of AIH. Immune cells are however present in the liver albeit to a lesser extent also in CHC patients with serum auto-antibodies[30]. We speculate that the severe disease seen in AIH and CHC with auto-Abs is mediated by similar mechanisms and that the auto-Abs can contribute to liver damage in these cases.

Sixty-five percent of the AIH patients had any of the three auto-Abs investigated in this study. As previously reported, ANA was the most prevalent auto-Ab [9]. LKM-1 Ab is a serological marker for one subtype of the autoimmune disease, AIH-2 which is more prevalent among adolescent women and young girls[16,17]. In this study LKM-1 Ab was detected in 45% of samples which is an unusually high proportion. This might be explained by that the study contained many young women. It is also possible that the genotype associated with the development of LKM-1 antibodies is more prevalent in the area from where patients were recruited[31]. LKM-1 has been shown to recognize CYP2D7 which is expressed on the surface of hepatocytes. Such self-recognition, unique for LKM-1 among NOSA, could explain the worse disease in these patients[32]. Possibly of importance, epitopes within CYP2D7 share homology with HCV proteins[33]. CYP2D6 epitopes can induce both poly-reactive B cells and T cells[34]. It has been proposed that polymorphisms in the *CYP2D6* gene lead to altered amino acids sequences and more immunogenic epitopes[35]. It is not known whether CYP2D6 polymorphisms could differentiate AIH-1 and AIH-2. There are however other differences between the AIH subtypes; AIH-2 share antibody profile with autoimmune polyendocrine syndrome type 1 which is caused by a mutation in the *AIRE* gene, leading to break of tolerance[31]. In this study the levels of both ANA and LKM-1 tended to be higher in CHC than in AIH. Other studies have detected higher level of LKM-1 in AIH-2, than in CHC[36]. Further studies are required to explain why LKM-1 and ANA is higher in sera from the CHC patients than from AIH patients in this study. High level of LKM-1 Ab in CHC has previously been reported in paediatric cohorts[37]. Similar to our findings, LKM-1 Ab have previously been reported in HCV where the titre is associated with disease severity[38]. Whether there is any relationship between patients with CHC, AIH and LKM-1 Ab is not known or whether these CHC cases are more prone to develop AIH. Although no longer commonly used, it has been proposed however that IFNα therapy for CHC, can induce autoimmune symptoms in the LKM-1+ individuals[39].

SMA was detected in none of the patients of AIH group, which is in disagreement with previous studies. As many as 70% to 80% percents of AIH cases have been described as SMA positive [40]. The successful treatment of our patients might be one explanation for the lack of SMA+ patients as this is this is associated with the disappearance of serum ANA and SMA[41]. It should be pointed out that seronegativity in AIH have been described in 1%-34% of cases (in our study 25%) underscoring the heterogeneity of this autoimmune disease[42].

High IgG level is a distinctive feature of AIH[43-45]. In our study, however, there was no significant difference in levels comparing AIH and CHC. Other studies have reported elevated levels of IgG in both AIH and CHC patients[38]. The level of IgG has previously been associated with severity of disease among chronic HCV infected patients which is in line with our findings. Both diseases are characterized by activation of B cells and a large number of plasma cells[6]. We speculate that many of these released auto-Abs are of the IgG subclass which can explain the elevated level of these abs in serum from both patient groups. This polyclonal activation is likely taking place either as a consequence or chronic antigen stimulation or due to loss of immune regulation[46,47]. Our interest is Th17 cells that have an established pathogenic function in autoimmune diseases[48]. Th17 cells are present in the liver of both AIH and CHC patients[30]. Further studies will determine whether these cells could contribute to B cell activation or generation of an inflammatory environment that promote auto-Ab production[49,50].

In conclusions, we found AIH related autoantibodies associated with HCV infection. The emergence of auto-Abs in CHC might be infection duration dependent, but it is not related to gender, the age of patients and serum viral load. Auto-Abs, especially LKM-1, in CHC cases might have pathogenic role leading to more severe disease which is indicated by an alteration of liver function tests and elevation of total IgG. It is not known whether auto-Ab prevalence is due to prolonged disease or whether certain patients are more susceptible for their development. We conclude that auto-Ab levels in CHC may be important markers of disease severity and that these patients have a disease similar to AIH. Future studies will unravel any further associations between these two diseases, whether genetic or other.

**COMMENTS**

***Background***

Worldwide, 130–200 million individuals are infected with hepatitis C. Although current therapies controlling the disease rather well, 80% of the infected patients develop chronic hepatitis C (CHC). It is not known why some of the patients develop more severe disease. Autoimmune hepatitis (AIH) is a disease of the liver that have a prevalence of 10-20/100000 individuals. This disease can be controlled by using immune suppressive therapies. In this paper we show that the presence of non-organ specific autoantibodies (NOSA) in both CHC and AIH is associated with server disease. Although overall CHC is less damaging to the liver than AIH cases, a subgroup can be defined with more severe pathology. This CHC subgroup is defined by liver/kidney microsomal-1 (LKM-1) positivity.

***Research frontiers***

In the field of autoimmunity, both novel therapies have recently been developed as well as better understanding of the aetiology of disease. Recent discoveries of novel immune cells and their dysregulation in the autoimmunity have increased the knowledge of disease aetiology and provided prospect for development of novel therapies. Novel genome-, transcriptome- and epigenome-sequencing techniques have given important insight of autoimmune associations to certain genomic regions genomic and the immunological heterogeneity underlying disease. As some subpopulations of CHC patients have antibodies that react to self, we speculate that the analysis of novel immune cells and comparison of immune cells from CHC patients with AIH using novel genomic and epigenomic tools can provide disease related knowledge useful for novel future treatment-strategies of these patients.

***Innovations and breakthroughs***

Th17 cells have recently been implicated in the development of AIH and response to HCV infection in the liver. Although it is not known how these cells confer pathology, studies from other autoimmune diseases has suggested that the cells support B cell germinal centre formation and production of auto-antibodies. This can be both through IL-21 production by Th17 cells and through transdifferentiation of Th17 cells to follicular T cells. Studies have shown that polymorphisms in the TNFα gene are associated with development of AIH. We are currently analysing how TNFα is suppressing Th17 cell expansion in rheumatoid arthritis patients. Future studies by authors would aim to determine the role of Th17 cells and possibly TNFα in the development of autoantibodies in AIH and LKM-1+ CHC.

***Applications***

The current study has characterized the immune response in CHC and AIH in homogenous patient cohorts. The findings differentiated CHC and AIH patients into different subgroups. These findings open for future studies of immune cell mediated induction of autoimmunity in CHC and AIH. We aim to characterize immune cells present in the liver and the peripheral blood of the patient cohorts. Further, genome wide association studies, analysis for expression quantitative trait loci and whole genome epigenome will be undertaken to gain better understanding of the autoimmune disease process which is regulating the immune cells. Findings from these studies will be correlated to disease severity, auto-Ab levels and other markers of liver disease. Importantly the knowledge gained will provide the possibility to discover overlapping genomic/epigenomic features between AIH and the subgroup of LKM-1 positive CHC patients with severe disease.

***Peer-review***

The manuscript by Amin *et al* compares the incidence of autoantibodies associated with autoimmune hepatitis, immunoglobulin levels and markers of liver disease in groups of age-matched subjects with autoimmune hepatitis, CHC infection and healthy controls.

**REFERENCES**

1 **Bogdanos DP**, Invernizzi P, Mackay IR, Vergani D. Autoimmune liver serology: current diagnostic and clinical challenges. *World J Gastroenterol* 2008; **14**: 3374-3387 [PMID: 18528935]

2 **Elkon K**, Casali P. Nature and functions of autoantibodies. *Nat Clin Pract Rheumatol* 2008; **4**: 491-498 [PMID: 18756274]

3 **Shoenfeld Y**, Gershwin ME, Meroni PL. Autoantibodies. Kindlington: Elsevier press, 2014

4 **Mackay IR**, Leskovsek NV, Rose NR. Cell damage and autoimmunity: a critical appraisal. *J Autoimmun* 2008; **30**: 5-11 [PMID: 18194728]

5 **Manns MP**, Rambusch EG. Autoimmunity and extrahepatic manifestations in hepatitis C virus infection. *J Hepatol* 1999; **31 Suppl 1**: 39-42 [PMID: 10622558 DOI: 10.1016/S0168-8278(99)80372-9]

6 **Yang DH**, Ho LJ, Lai JH. Useful biomarkers for assessment of hepatitis C virus infection-associated autoimmune disorders. *World J Gastroenterol* 2014; **20**: 2962-2970 [PMID: 24659887 DOI: 10.3748/wjg.v20.i11.2962]

7 **Bogdanos DP**, Mieli-Vergani G, Vergani D. Non-organ-specific autoantibodies in hepatitis C virus infection: do they matter? *Clin Infect Dis* 2005; **40**: 508-510 [PMID: 15712071 DOI: 10.1086/427293]

8 **Himoto T**, Nishioka M. Autoantibodies in liver disease: important clues for the diagnosis, disease activity and prognosis. *Auto Immun Highlights* 2013; **4**: 39-53 [PMID: 26000142 DOI: 10.1007/s13317-013-0046-7]

9 **Chrétien P**, Chousterman M, Abd Alsamad I, Ozenne V, Rosa I, Barrault C, Lons T, Hagège H. Non-organ-specific autoantibodies in chronic hepatitis C patients: association with histological activity and fibrosis. *J Autoimmun* 2009; **32**: 201-205 [PMID: 19324518 DOI: 10.1016/j.jaut.2009.02.005]

10 **Gatselis NK**, Zachou K, Papamichalis P, Koukoulis GK, Gabeta S, Dalekos GN, Rigopoulou EI. Comparison of simplified score with the revised original score for the diagnosis of autoimmune hepatitis: a new or a complementary diagnostic score? *Dig Liver Dis* 2010; **42**: 807-812 [PMID: 20399157 DOI: 10.1016/j.dld.2010.03.005]

11 **Oo YH**, Hubscher SG, Adams DH. Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management. *Hepatol Int* 2010; **4**: 475-493 [PMID: 20827405 DOI: 10.1007/s12072-010-9183-5]

12 **Cassani F**, Cataleta M, Valentini P, Muratori P, Giostra F, Francesconi R, Muratori L, Lenzi M, Bianchi G, Zauli D, Bianchi FB. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. *Hepatology* 1997; **26**: 561-566 [PMID: 9303483 DOI: 10.1002/hep.510260305]

13 **Badiani RG**, Becker V, Perez RM, Matos CA, Lemos LB, Lanzoni VP, Andrade LE, Dellavance A, Silva AE, Ferraz ML. Is autoimmune hepatitis a frequent finding among HCV patients with intense interface hepatitis? *World J Gastroenterol* 2010; **16**: 3704-3708 [PMID: 20677344 DOI: 10.3748/wjg.v16.i29.3704]

14 **Metwally K**, Abdo SA, Badr S, Abdurrhman MA, Saafan NK, Abdel- Bary AM, Abbas MH. Serum Autoantibodies in Chronic Hepatitis C: Comparison with Hepatitis C/Autoimmune Hepatitis Overlap Syndrome in Egypt. *J Lif Sci* 2012; **9**: 1086-1091

15 **Sharma NK**, Sherker AH. Epidemiology, Risk Factors, and Natural History of Chronic Hepatitis C. In: Chronic Viral Hepatitis. Washington Hospital Center, Washington: 2010: 33-70

16 **Mackay IR**. Autoimmune Hepatitis: From the Clinic to the Diagnistics Laboratory. Lab Med 2011; 42: 224-233 [DOI: 10.1309/LM7EUBRRUPLF9V6R]

17 **Salamunić I**. Laboratory diagnosis of autoimmune diseases – new technologies, old dilemmas. Biochemia Medica 2010; 20(1): : 45-56 [DOI: 10.11613/BM.2010.006]

18 **Heintges T**, Niederau C. Differentiation between autoimmune hepatitis and hepatitis C virus related liver disease. *Z Gastroenterol* 1993; **31**: 285-288 [PMID: 7686702]

19 **Bogdanos DP**, Mieli-Vergani G, Vergani D. Non-organ-specific autoantibodies in children with chronic hepatitis C virus infection. *Clin Infect Dis* 2004; **38**: 1505; author reply 1505-1506 [PMID: 15156495 DOI: 10.1086/383578]

20 **Marconcini ML**, Fayad L, Shiozawa MB, Dantas-Correa EB, Lucca Schiavon Ld, Narciso-Schiavon JL. Autoantibody profile in individuals with chronic hepatitis C. *Rev Soc Bras Med Trop* 2013; **46**: 147-153 [PMID: 23740063 DOI: 10.1590/0037-8682-0039-2013]

21 **Muratori P**, Muratori L, Stroffolini T, Pappas G, Terlizzi P, Ferrari R, Loffreda S, Cassani F, Rapicetta M, Guadagnino V, Bianchi FB, Lenzi M. Prevalence of non-organ specific autoantibodies in HCV-infected subjects in the general population. *Clin Exp Immunol* 2003; **131**: 118-121 [PMID: 12519394 DOI: 10.1046/j.1365-2249.2003.02030.x]

22 **Zeman MV**, Hirschfield GM. Autoantibodies and liver disease: uses and abuses. *Can J Gastroenterol* 2010; **24**: 225-231 [PMID: 20431809 DOI: 10.1155/2010/431913]

23 **Emlen W**, O'Neill L. Clinical significance of antinuclear antibodies: comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays. *Arthritis Rheum* 1997; **40**: 1612-1618 [PMID: 9324015 DOI: 10.1002/1529-0131(199709)40: 9< 1612: : AID-ART10> 3.0.CO; 2-W]

24 **Lenzi M**, Johnson PJ, McFarlane IG, Ballardini G, Smith HM, McFarlane BM, Bridger C, Vergani D, Bianchi FB, Williams R. Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity. *Lancet* 1991; **338**: 277-280 [PMID: 1677111 DOI: 10.1016/0140-6736(91)90418-O]

25 **Lindgren S**, Braun HB, Michel G, Nemeth A, Nilsson S, Thome-Kromer B, Eriksson S. Absence of LKM-1 antibody reactivity in autoimmune and hepatitis-C-related chronic liver disease in Sweden. Swedish Internal Medicine Liver club. *Scand J Gastroenterol* 1997; **32**: 175-178 [PMID: 9051879 DOI: 10.3109/00365529709000189]

26 **Drygiannakis D,** Lionis C, Drygiannakis I, Pappas G, Kouroumalis E. Low prevalence of liver-kidney microsomal autoantibodies of type 1 (LKM1) in hepatitis C seropositive subjects on Crete, Greece. *BMC Gastroenterol* 2001; **1**: 4 [PMID: 11418082 DOI: 10.1186/1471-230X-1-4]

27 **Dalekos GN**, Obermayer-Straub P, Bartels M, Maeda T, Kayser A, Braun S, Loges S, Schmidt E, Gershwin ME, Manns MP. Cytochrome P450 2A6: a new hepatic autoantigen in patients with chronic hepatitis C virus infection. *J Hepatol* 2003; **39**: 800-806 [PMID: 14568264 DOI: 10.1016/S0168-8278(03)00356-8]

28 **Yee LJ**, Kelleher P, Goldin RD, Marshall S, Thomas HC, Alberti A, Chiaramonte M, Braconier JH, Hall AJ, Thursz MR. Antinuclear antibodies (ANA) in chronic hepatitis C virus infection: correlates of positivity and clinical relevance. *J Viral Hepat* 2004; **11**: 459-464 [PMID: 15357653 DOI: 10.1111/j.1365-2893.2004.00530.x]

29 **Czaja AJ**, Carpenter HA. Histological findings in chronic hepatitis C with autoimmune features. *Hepatology* 1997; **26**: 459-466 [PMID: 9252159 DOI: 10.1002/hep.510260229]

30 **Oo YH**, Banz V, Kavanagh D, Liaskou E, Withers DR, Humphreys E, Reynolds GM, Lee-Turner L, Kalia N, Hubscher SG, Klenerman P, Eksteen B, Adams DH. CXCR3-dependent recruitment and CCR6-mediated positioning of Th-17 cells in the inflamed liver. *J Hepatol* 2012; **57**: 1044-1051 [PMID: 22796894 DOI: 10.1016/j.jhep.2012.07.008]

31 **Mackay IR**. A 50-year experience with autoimmune hepatitis: and where are we now? *J Gastroenterol* 2011; **46 Suppl 1**: 17-28 [PMID: 21072544 DOI: 10.1007/s00535-010-0325-2]

32 **Muratori L**, Parola M, Ripalti A, Robino G, Muratori P, Bellomo G, Carini R, Lenzi M, Landini MP, Albano E, Bianchi FB. Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane. *Gut* 2000; **46**: 553-561 [PMID: 10716687 DOI: 10.1136/gut.46.4.553]

33 **Manns MP**, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. *J Clin Invest* 1991; **88**: 1370-1378 [PMID: 1717511 DOI: 10.1172/JCI115443]

34 **Ma Y**, Bogdanos DP, Hussain MJ, Underhill J, Bansal S, Longhi MS, Cheeseman P, Mieli-Vergani G, Vergani D. Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. *Gastroenterology* 2006; **130**: 868-882 [PMID: 16530525 DOI: 10.1053/j.gastro.2005.12.020]

35 **Bogdanos DP**, McFarlane IG. Cytochrome P450 2A6 meets P450 2D6: an enigma of viral infections and autoimmunity. *J Hepatol* 2003; **39**: 860-863 [PMID: 14568272 DOI: 10.1016/S0168-8278(03)00417-3]

36 **Lunel F**, Abuaf N, Frangeul L, Grippon P, Perrin M, Le Coz Y, Valla D, Borotto E, Yamamoto AM, Huraux JM. Liver/kidney microsome antibody type 1 and hepatitis C virus infection. *Hepatology* 1992; **16**: 630-636 [PMID: 1380479 DOI: 10.1002/hep.1840160304]

37 **Gregorio GV**, Pensati P, Iorio R, Vegnente A, Mieli-Vergani G, Vergani D. Autoantibody prevalence in children with liver disease due to chronic hepatitis C virus (HCV) infection. *Clin Exp Immunol* 1998; **112**: 471-476 [PMID: 9649217 DOI: 10.1046/j.1365-2249.1998.00574.x]

38 **Ferri S**, Muratori L, Quarneti C, Muratori P, Menichella R, Pappas G, Granito A, Ballardini G, Bianchi FB, Lenzi M. Clinical features and effect of antiviral therapy on anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis C. *J Hepatol* 2009; **50**: 1093-1101 [PMID: 19398235 DOI: 10.1016/j.jhep.2009.02.020]

39 **Muratori L**, Lenzi M, Cataleta M, Giostra F, Cassani F, Ballardini G, Zauli D, Bianchi FB. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C. *J Hepatol* 1994; **21**: 199-203 [PMID: 7989709 DOI: 10.1016/S0168-8278(05)80395-2]

40 **Vergani D**, Alvarez F, Bianchi FB, Cançado EL, Mackay IR, Manns MP, Nishioka M, Penner E. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. *J Hepatol* 2004; **41**: 677-683 [PMID: 15464251 DOI: 10.1016/j.jhep.2004.08.002]

41 **Czaja AJ**, Carpenter HA, Moore SB. HLA DRB1\*13 as a risk factor for type 1 autoimmune hepatitis in North American patients. *Dig Dis Sci* 2008; **53**: 522-528 [PMID: 17510796 DOI: 10.1007/s10620-007-9859-4]

42 **Czaja AJ**. Autoantibody-negative autoimmune hepatitis. *Dig Dis Sci* 2012; **57**: 610-624 [PMID: 22187100 DOI: 10.1007/s10620-011-2017-z]

43 **Hennes EM**, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, Bittencourt PL, Porta G, Boberg KM, Hofer H, Bianchi FB, Shibata M, Schramm C, Eisenmann de Torres B, Galle PR, McFarlane I, Dienes HP, Lohse AW. Simplified criteria for the diagnosis of autoimmune hepatitis. *Hepatology* 2008; **48**: 169-176 [PMID: 18537184 DOI: 10.1002/hep.22322]

44 **Homberg JC**, Abuaf N, Bernard O, Islam S, Alvarez F, Khalil SH, Poupon R, Darnis F, Lévy VG, Grippon P. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. *Hepatology* 2010; **7**: 1333-1339 [PMID: 3679093 DOI: 10.1002/hep.1840070626]

45 **Manns MP**, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM. Diagnosis and management of autoimmune hepatitis. *Hepatology* 2010; **51**: 2193-2213 [PMID: 20513004]

46 **Delogu LG**, Deidda S, Delitala G, Manetti R. Infectious diseases and autoimmunity. *J Infect Dev Ctries* 2011; **5**: 679-687 [PMID: 21997935]

47 **Sfriso P**, Ghirardello A, Botsios C, Tonon M, Zen M, Bassi N, Bassetto F, Doria A. Infections and autoimmunity: the multifaceted relationship. *J Leukoc Biol* 2010; **87**: 385-395 [PMID: 20015961]

48 **Bystrom J**, Taher TE, Muhyaddin MS, Clanchy FI, Mangat P, Jawad AS, Williams RO, Mageed RA. Harnessing the Therapeutic Potential of Th17 Cells. *Mediators Inflamm* 2015; **2015**: 205156 [PMID: 26101460]

49 **Mitsdoerffer M**, Lee Y, Jäger A, Kim HJ, Korn T, Kolls JK, Cantor H, Bettelli E, Kuchroo VK. Proinflammatory T helper type 17 cells are effective B-cell helpers. *Proc Natl Acad Sci U S A* 2010; **107**: 14292-14297 [PMID: 20660725]

50 **Jaffar Z**, Ferrini ME, Herritt LA, Roberts K. Cutting edge: lung mucosal Th17-mediated responses induce polymeric Ig receptor expression by the airway epithelium and elevate secretory IgA levels. *J Immunol* 2009; **182**: 4507-4511 [PMID: 19342622]

**P-Reviewer:** Grant MD **S-Editor:** Yu J **L-Editor:** **E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** Sweden

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Distribution of study group according to age and gender**

|  |  |  |  |
| --- | --- | --- | --- |
| **Parameter** | **CHC (*n* = 50)** | **AIH (*n* = 20)** | **HC (*n* = 20)** |
| Age (yr), mean ± SD  Range  mean ± SD | 10–65  33 ± 2.38 | 16-69  37 ± 3.22 | 16–69  37 ± 3.22 |
| Gender, *n* (%)  Female  Male | 24 (48)  26 (52) | 15 (75)  5 (25) | 15 (75)  5 (25) |
| Age (yr), mean ± SD  Female  Male | 34 ± 2.28  33 ± 2.38 | 35 ± 3.42  47 ± 3.12 | 35 ± 3.42  47 ± 3.12 |

CHC: Chronic hepatitis C; AIH: Autoimmune hepatitis; HC: Hepatitis virus.

**Table 2 Distribution and comparison of autoantibodies between the chronic hepatitis C and the autoimmune hepatitis patient group *n* (%)**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **HCV-AIH**  ***P* value** | **HC**  **(*n* = 20)** | **AIH**  **(*n* = 20)** | **CHC**  **(*n* = 50)** | **Autoantibodies** |
|  | 0 (0) | 0 (0) | 4 (8) | SMA |
| 0 (0) | 9 (45) | 11 (22) | LKM-1 |
| 4 (20) | 13 (65) | 16 (32) | ANA |
| 0.00311 | 4 (20) | 23 (75) | 31 (36) | Total |

1Indicates significant difference on the 0.01 level, NS indicate non-significance. Statistically significant differences were determined using ANOVA followed by Duncan’s test. CHC: Chronic hepatitis C; AIH: Autoimmune hepatitis; HC: Hepatitis virus; HCV: Hepatitis C virus.

**Table 3 Estimation of IgG and IgM and comparison between study groups (mean ± SD)**

|  |  |  |
| --- | --- | --- |
| **Groups** | **IgG (mg/dL)** | **IgM (mg/dL)** |
| CHC | 1841 ± 66.44 | 176 ± 5.561 |
| AIH | 2054 ± 152.62 | 228 ± 5.561 |
| HC | 1098 ± 57.69**1** | 127 ± 4.801 |

1Denotes significant difference comparing with the other two groups, *P <* 0.05. Statistically significant differences were determined using ANOVA followed by Duncan’s test. CHC: Chronic hepatitis C; AIH: Autoimmune hepatitis; HC: Hepatitis virus.

**Table 4 Comparison of the markers of liver injury among study groups (mean ± SD)**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Groups** | **AP (UI/L)** | **ALT (UI/L)** | **AST (UI/L)** | **ALB (G/DL)** | **TSB(MG/DL)** |
| CHC | 296 ± 19.90**1** | 30 ± 1.32**1** | 45 ± 1.71 **1** | 3.8 ± 0.11**2** | 1.0 ± 0.27**2** |
| AIH | 373 ± 32.10**1** | 37 ± 3.20**1** | 56 ±4.10 **1** | 3.3 ± 0.15 **1** | 4.0 ± 1.57**1** |
| HC | 171 ± 8.30**1** | 19 ± 1.00**1** | 28 ± 1.28 **1** | 4.0 ± 0.06**2** | 0.6 ± 0.05**2** |

1Denotes significant difference comparing with the other two groups, *P <* 0.05; 2Indicate significant difference comparing with the group indicated with an 1only. Statistically significant differences were determined using ANOVA followed by Duncan’s test. CHC: Chronic hepatitis C; AIH: Autoimmune hepatitis; HC: Hepatitis virus; ALB: Albumin; AP: Alkaline phosphatase; AST: Aspartate transaminase; TSB: Total serum bilirubin; ALT: Alanine transaminase.

**Table 5** **Comparison of different parameters in chronic hepatitis C with and without autoantibodies** **(mean ± SD)**

|  |  |  |  |
| --- | --- | --- | --- |
| **Parameters** | **CHC with**  **autoantibodies**  **M/F (9/9)** | **CHC without**  **autoantibodies**  **M/F (17/15)** | ***P* value** |
| Mean age (yr) | 33 ± 16 | 34 ±14.3 | 0.36 NS |
| Viral load (copy/mL) | 8.3 × 105  ± 10.4 × 106 | 3 × 106 ± 19 × 105 | 0.52 NS |
| Duration of infection (mo) | 21.3 ± 12.3 | 11 ± 7.3 | 0.0022 |
| IgG (mg/dL) | 2109 ± 462.4 | 1630 ± 323 | 0.0011 |
| IgM (mg/dL) | 190 ± 25 | 172 ± 45.3 | 0.3 NS |
| AP (u/L) | 428 ± 91.5 | 221 ± 104 | 0.0011 |
| AST (u/L) | 52 ± 12.7 | 41 ± 9.81 | 0.0071 |
| ALT (u/L) | 36 ± 9.7 | 27 ± 7.2 | 0.0071 |
| S. Albumin (g/dL) | 3.8 ± 0.87 | 3.9 ± 0.72 | 0.47 NS |
| TSB (mg/dL) | 1.5 ± 3.1 | 0.8 ± 0.58 | 0.0011 |

1,2Indicate significant difference on the 0.01 and the 0.001 level respectively, NS indicates non-significance. Statistically significant differences were determined using ANOVA followed by Duncan’s test. CHC: Chronic hepatitis C; AIH: Autoimmune hepatitis; AP: Alkaline phosphatase; AST: Aspartate transaminase; TSB: Total serum bilirubin; ALT: Alanine transaminase.

**Table 6 Autoantibody positive chronic hepatitis C and autoimmune hepatitis, comparison of different parameters (mean ± SD)**

|  |  |  |  |
| --- | --- | --- | --- |
| ***P* value** | **Autoantibody positive AIH (*n* = 20)** | **Autoantibody positive CHC (*n* = 18)** | **Parameters** |
| 0.42 NS | 2053 ±710.5 | 2109 ± 249 | IgG (mg/Dl) |
| 0.0271 | 227 ± 63.1 | 190 ± 26.8 | IgM (mg/dL) |
| 0.33 NS | 373 ± 166.1 | 428 ± 37.9 | AP (U/L) |
| 0.42 NS | 57 ± 18.64 | 52 ± 8.42 | AST (U/L) |
| 0.81 NS | 37 ± 15.6 | 36 ± 5.5 | ALT (U/L) |
| 0.00332 | 4.0 ± 7.0 | 1.5 ± 4.1 | TSB (mg/dL) |
| 0.12 NS | 3. 3 ± 0.69 | 3.8 ± 0.78 | Albumin (g/L) |

1,2Indicate significant difference on the 0.05 and the 0.01 level respectively, NS indicates non-significance. Statistically significant differences were determined using ANOVA followed by Duncan’s test. CHC: Chronic hepatitis C; AIH: Autoimmune hepatitis; AP: Alkaline phosphatase; AST: Aspartate transaminase; TSB: Total serum bilirubin; ALT: Alanine transaminase.

**Table 7 Comparison between LKM-1 positive patients in chronic hepatitis C and autoimmune hepatitis groups (mean ± SD)**

|  |  |  |  |
| --- | --- | --- | --- |
| ***P* value** | **Groups** | | **Parameters** |
| **LKM-1+ in CHC**  **M/F (5/6)** | **LKM-1+ in AIH**  **M/F (0/9)** |
| 0.51 NS  0.34 NS  0.0011  0.57 NS  0.22 NS  0.45 NS  0.5 NS  0.06 NS | 35 ±19  2522 ± 295.6  185 ± 26.26  472 ± 3  57 ± 37.92  40 ± 5.41  3.9 ± 0.9  1.9 ± 3.90 | 31 ± 10  2205 ± 566.1  262 ± 41.21  404 ± 146.7  64 ± 12.71  41 ± 9.64  3.4 ± 0.8  3.4 ± 4.97 | Mean age (yr)  IgG (mg/dL)  IgM (mg/dL)  AP (u/mL)  AST (u/mL)  ALT (u/mL)  S. Albumin (g/dL)  TSB (mg/dL) |

1Indicates significant difference on the 0.01 level, NS indicates non-significance. Statistically significant differences were determined using ANOVA followed by Duncan’s test. CHC: Chronic hepatitis C; AIH: Autoimmune hepatitis; AP: Alkaline phosphatase; AST: Aspartate transaminase; TSB: Total serum bilirubin; ALT: Alanine transaminase.